<DOC>
	<DOCNO>NCT01513161</DOCNO>
	<brief_summary>The purpose study determine whether nalfurafine hydrochloride effective safe treatment conventional-treatment-resistant pruritus patient receive hemodialysis .</brief_summary>
	<brief_title>Efficacy Safety Study TRK-820 Treat Conventional-treatment-resistant Pruritus Patients Receiving Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>[ At time obtain consent form ] Chronic renal failure patient regularly receive hemodialysis three time week likely serious treatment change acute symptom study period Patients receive drug pruritus treatment section 1 2 within one year day sing consent form 1 . Systemic therapy two consecutive week depend antihistamine antiallergic drug fall `` prescription drug indication pruritus '' ( oral drug , injection , etc . ) 2 . Local therapy depend `` prescription drug indication pruritus '' ( ointment , etc . ) moisturizer prescribe doctor ( topical preparation , etc . ) Patients conventional pruritus treatment section ( 2 ) enough Patients age 20 year old time sign consent form [ At time enrollment ] Patients whose VAS score measure breakfast dinner five day last 7 day predose observation period whose mean whichever high VAS score breakfast dinner ≥50 mm Patients whose whichever high VAS score breakfast dinner last 7 day preliminary observation day ( measure VAS score one miss ) ≥20 mm five day Patients judged pruritus day night two day base Shiratori 's severity criterion assess subject day fifth sixth hemodialysis day hemodialysis completion predose observation period , whose whichever high pruritis score measure day night 3 ( moderate ) two day Patients malignant tumor Patients depression , schizophrenia dementia complication Patients currently Childpugh class B C hepatic cirrhosis complication Patients clinically significant hepatic cardiovascular disease control diet drug therapy Patients currently follow heart disease : lifethreatening arrhythmia ; unstable angina myocardiac infarction within 6 month ; PCI CABG within 6 month ; NYHA class III IV congestive heart failure Patients atopic dermatitis chronic urticaria complication Patients allergic opioid drug Patients dependence drug alcohol Patients receive phototherapy pruritus within one month sign consent form Patients participate study TRK820 receive study drug already enrol study Patients participate clinical study ( include one use artificial kidney medical equipment ) , receive study drug treatment clinical equipment within one month sign consent form Pregnant woman , lactate woman patient childbearing potential use contraceptive method Patients report VAS score reason principal investigator study personnel 's discretion Patients whose complication history impact result study principal investigator subinvestisator 's discretion Other patient proper participate study principal investigator study personnel 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>pruritus</keyword>
</DOC>